The discovery and optimization of pyrimidinone-containing MCH R1 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 18, 2006, Pages 4723-4727

  Hertzog, Donald L ^a   Al Barazanji, Kamal A ^a   Bigham, Eric C ^a   Bishop, Michael J ^a   Britt, Christy S ^a   Carlton, David L ^a   Cooper, Joel P ^a   Daniels, Alex J ^a   Garrido, Dulce M ^a   Goetz, Aaron S ^a   Grizzle, Mary K ^a   Guo, Yu C ^a   Handlon, Anthony L ^a   Ignar, Diane M ^a   Morgan, Ronda O ^a   Peat, Andrew J ^a   Tavares, Francis X ^a   Zhou, Huiqiang ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

MCH; MCH antagonist; MCH R1; MCH R1 antagonist; Melanin concentrating hormone

Indexed keywords

GW 803430; HORMONE ANTAGONIST; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; PYRIMIDINONE DERIVATIVE; SIBUTRAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; HORMONE INHIBITION; LIPID DIET; MOUSE; NONHUMAN; OBESITY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; MICE; MICE, INBRED AKR; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIMIDINONES; RECEPTORS, PITUITARY HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS;

ANIMALIA;

EID: 33746820210     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.07.008     Document Type: Article

References (22)

1. Qu D., Ludwig D.S., Gammeltoft S., Piper M., Pelleymounter M.A., Cullen M.J., Mathes W.F., Przypek J., Kanarek R., and Maratos-Flier E. Nature 380 (1996) 243
2. Shimada M., Tritos D., Aitken A., Donella-Deana A., Hemmings B.A., and Parker P.J. Nature 396 (1998) 670
3. Chen Y., Hu C., Hsu C.K., Zhang Q., Bi C., Asnicar M., Hsiung H.M., Fox N., Slieker L.J., Yang D.D., Heiman M.L., and Shi Y. Endocrinology 143 (2002) 2469
4. Marsh D.J., Weingarth D.T., Novi D.E., Chen H.Y., Trumbauer M.E., Chen A.S., Guan X.M., Jiang M.M., Feng Y., Camacho R.E., Shen Z., Frazier E.G., Yu H., Metzger J.M., Kuca S.J., Shearman L.P., Gopal-Truter S., Macneil D.J., Strack A.M., MacIntyre D.E., Van der Ploeg L.H., and Qian S. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 3240
5. Several patents describing MCH R1 patents have been published. For reviews on the subject, please see:. Dyke H.J., and Ray N.C. Expert Opin. Ther. Patents 15 (2005) 1303
6. Kowalski T.J., and McBriar M.D. Expert Opin. Invest. Drugs 13 (2004) 1113
7. Browning A. Expert Opin. Ther. Patents 14 (2004) 313
8. Collins C.A., and Kym P.R. Curr. Opin. Invest. Drugs 4 (2003) 386
9. Witty, D. R.; Bateson, J.; Hervieu, G. J.; Jeffrey, P.; Johnson, C. N.; Muir, A. I.; O'Hanlon, P. J.; Stemp, G.; Stevens, A. J.; Thewlis, K.; Winborn, K. Y. Bioorg. Med. Chem. Lett., in press.
10. Witty, D. R.; Bateson, J.; Hervieu, G. J.; Al-Barazanji, K.; Jeffrey, P.; Hamprecht, D.; Haynes, A.; Johnson, C. N.; Muir, A. I.; O'Hanlon, P. J.; Stemp, G.; Stevens, A. J.; Thewlis, K.; Winborn, K. Y. Bioorg. Med. Chem. Lett., in press.
11. Prepared through Jones oxidation of the corresponding aldehyde found in. Sone C., and Matsuki Y. Bull. Chem. Soc. Japan 36 (1963) 618
12. Gupton J.T., Miller J.F., Bryant R.D., Maloney P.R., and Foster B.S. Tetrahedron 43 (1987) 1747
13. 80 thrombin response in the host cells. All compounds were assayed with n ≥ 4.
14. Redman A.M., Dumas J., and Scott W.J. Org. Lett. 2 (2000) 2061
15. Molecular models of the structures in Figure 1 were created using the Maestro Version 7.5 interface from Schrödinger, LLC. In Maestro, conformation searches and energy minimizations were carried out with the MacroModel application using the OPLS-2005 force field. The atoms of the pyrimidinone ring were superimposed to demonstrate the variation in the position of the 4-chlorophenyl substituent on the fused heterocyclic ring.
16. Patel M.V., Rohde J.J., Gracias V., and Kolasa T. Tetrahedron Lett. 44 (2003) 6665
17. Kruse C.G., Timmermans P.B.M.W.M., van der Laken C., and van der Gen A. Recl. Trav. Chim. 97 (1978) 151
18. Tavares, F. X.; Al-Barazanji, K. A.; Bigham, E. C.; Bishop, M. J.; Britt, C. S.; Carlton, D. L.; Feldman, P. L.; Goetz, A. S.; Grizzle, M. K.; Guo, Y. C.; Handlon, A. L.; Hertzog, D. L.; Ignar, D. M.; Lang, D. G.; Ott, R. J.; Peat, A. J.; Zhou, H-Q. J. Med. Chem., in press.
19. Handlon, A. L.; Al-Barazanji, K.; Barvian, K. K.; Bigham, E. C.; Carlton, D. L.; Carpenter, A. J.; Cooper, J. P.; Daniels, A. J.; Garrison, D. T.; Goetz, A. S.; Green, G. M.; Grizzle, M. K.; Guo, Y. C.; Hertzog, D. L.; Hyman, C. E.; Ignar, D. M.; Peckham, G. E.; Speake, J. D.; Britt, C.; Swain, W. R. Abstracts of Papers. In 228th National Meeting of the American Chemical Society; American Chemical Society: Washington, DC, 2004, p. 193.
20. The maleate salts of compound 7c and related analogs were often made to provide easily handled solids that were not hygroscopic.
21. 1-({[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl]oxy}acetyl)pyrrolidine has the following structure:{A figure is presented}.
22. The weight loss achieved with GW803430 (compound 7c) was due entirely to fat mass loss as determined by dual-energy X-ray absorptiometry (DEXA) scanning. See Al-Barazanji, K.; Grizzle, M.; Britt, C.; Lancaster, M.; Daniels, A.; Ignar, D.; Cooper, J; Hertzog, D. Obesity Res. 2004, 12, 56-OR.